The factors influencing disease-free survival are BVI, TNM and LNM.
影响无瘤生存期的因素为：BVI、TNM分期和N分期。
Delay of cancer treatment did not significantly affect disease-free survival for motherswith early breast cancer.
对早期乳腺癌患者而言，对癌症治疗的延迟并不会显著影响患者的无病期。
In the extended disease-free survival in Integrated Treatment slight advantage, but there is no statistical significance.
在延长无病生存期方面中西医结合治疗略有优势，但尚无统计学意义。
Furthermore, it improves the QoL and the nutritional status of affected patients with favorable overall and disease-free survival.
此外，它改善了总生存和无病生存患者的生活质量和营养状况。
Univariate prognostic evaluation showed that tumor size, nodal involvement, histological grade, CA15 3 and CEA were prognostic factors in disease-free survival.
单变量预后评价显示：肿瘤的大小、淋巴结浸润、组织型别、CEA、CA153等是无病存活的预后要素。
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance).
【译】KRAS基因密码子12和13与无病生存的野生型BRAF的II I期结肠癌辅助化疗试验从一个突变(n0147联盟)。
The clinical and histological effects, toxic and side reaction of chemotherapy such as nausea and vomit, the 3-year survival rates and disease-free survival rates were analyzed.
观察两组患者的临床疗效、组织学疗效、对化疗的毒副反应，以及术后3年生存率和无病存活率，并进行对比分析。
Results of the study show a significant association between power-frequency magnetic field exposure and reduced disease-free survival for children with acute lymphoblastic leukemia.
研究结果显示儿童急性淋巴性白血病的生存机会的减少与工频电磁场辐照有很强的关联。
Conclusions Adjuvant chemotherapy containing paclitaxel can improve the disease-free survival of breast cancer with HER-2 positive, especially for the patients with er and pr negative.
结论含紫杉醇类药物进行术后辅助化疗能增加HER - 2阳性乳腺癌患者无病生存获益，尤其是对ER、PR均阴性且her - 2阳性者。
Objective: to analyse the treatment outcome of childhood acute lymphoblastic leukemia (ALL) patients in our hospital, and explore the factors influencing the Disease-free survival (DFS).
目的：总结湘雅医院近年住院治疗儿童急性淋巴细胞性白血病(all)临床资料，探讨影响儿童all长期无病生存(DFS)的因素。
Objective to investigate the adverse effect, disease free survival and overall survival of dose-dense chemotherapy in postoperative breast cancer patients.
目的观察剂量密度化疗治疗乳腺癌的不良反应及对无病生存期和总生存期的影响。
To determine which radiotherapy regimens for oral cavity and oropharyngeal cancers result in increased overall survival, disease free survival, progression free survival and locoregional control.
确定何种口腔及口咽癌的放射治疗方式能够增加整体存活、无病存活、无疾病进展存活以及局部区域控制。
No statistically significant difference was shown for disease free survival.
在无病存活率方面没有统计上显著差异。
This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease.
目的：前列腺癌内分泌治疗后发现进展速度存在较大差异，为了改善其预后，本文探讨前列腺癌内分泌治疗后无进展生存期的影响因素。
For the women who were generally optimistic, there was a longer disease-free interval, the best predictor of survival.
对那些通常持乐观态度的妇女来说，两次发病间隔的时间较长，而这是生存下去的最好预兆。
These reports showed that even after short term follow up one year of Herceptin resulted in improved disease free, metastases free and overall survival.
这些报告表明，即使在短期内跟进一年赫赛汀导致改善无病，转移自由和整体存活率。
The rate of relapse-metastasis and disease free survival for two groups were observed. 9 possible factors influencing disease free survival were selected to analyze with COX Regression model.
选择9个可能对大肠癌术后无病生存产生影响的因素，通过COX模型进行多因素分析。
The oncological clearance, the complication rate, the disease free interval and survival were comparable in the two groups.
两组的肿 瘤清除情况、并发症发生率、无瘤间期和生存率无明显差别。
The two-year estimated disease free survival was much lower in children with high AS expression(53.8%)than in those with low AS expression(84.6%)(P<0.05).
AS低表达组患儿白血病持续完全缓解率为84.6%，而AS高表达组患儿持续完全缓解率仅为53.8%（P＜0.05）。
The two-year estimated disease free survival was much lower in children with high AS expression(53.8%)than in those with low AS expression(84.6%)(P<0.05).
AS低表达组患儿白血病持续完全缓解率为84.6%，而AS高表达组患儿持续完全缓解率仅为53.8%（P＜0.05）。
应用推荐